Fractyl Health, Inc. is a metabolic therapeutics company that specializes in innovative treatments for obesity and type 2 diabetes (T2D). Despite recent advancements in treatment, these diseases continue to pose significant health risks. The company’s mission is to shift the focus of metabolic disease treatment from managing symptoms to providing long-lasting therapies that target the root causes of the diseases.
Fractyl Health is headquartered in Burlington, MA and has been dedicated to developing new treatments for metabolic diseases. To learn more about the company and their mission, visit their website or follow them on Twitter. For corporate inquiries, contact Lisa Davidson, Chief Financial Officer at ir@fractyl.com or 781.902.8800. For media inquiries, reach out to Beth Brett, Corporate Communications at bbrett@fractyl.com or 720.656.6544. Investors can contact Stephen Jasper at Gilmartin Group for more information at stephen@gilmartinir.com or 619.949.3681.
On May 15th, 2024 at 4:20 p.m PDT (7:20 p.m EDT), Dr Harith Rajagopalan, CEO of Fractyl Health will be participating in a fireside chat at the upcoming BofA Securities 2024 Health Care Conference on May 15th, 2024 at 4:20 p
